A detailed history of Argent Advisors, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Argent Advisors, Inc. holds 11,203 shares of GILD stock, worth $1.02 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
11,203
Previous 11,286 0.74%
Holding current value
$1.02 Million
Previous $774,000 21.32%
% of portfolio
0.35%
Previous 0.31%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $5,526 - $6,971
-83 Reduced 0.74%
11,203 $939,000
Q2 2024

Jul 29, 2024

BUY
$63.15 - $72.88 $33,658 - $38,845
533 Added 4.96%
11,286 $774,000
Q1 2024

May 01, 2024

SELL
$71.58 - $87.29 $21,545 - $26,274
-301 Reduced 2.72%
10,753 $787,000
Q4 2023

Feb 08, 2024

SELL
$73.27 - $83.09 $12,382 - $14,042
-169 Reduced 1.51%
11,054 $895,000
Q3 2023

Nov 08, 2023

BUY
$73.94 - $80.67 $2,144 - $2,339
29 Added 0.26%
11,223 $841,000
Q2 2023

Aug 04, 2023

BUY
$76.01 - $86.7 $22,726 - $25,923
299 Added 2.74%
11,194 $862,000
Q1 2023

Apr 21, 2023

SELL
$77.31 - $88.08 $36,799 - $41,926
-476 Reduced 4.19%
10,895 $903,000
Q4 2022

Feb 01, 2023

SELL
$62.32 - $89.47 $3,302 - $4,741
-53 Reduced 0.46%
11,371 $976,000
Q3 2022

Nov 08, 2022

BUY
$59.54 - $68.01 $23,280 - $26,591
391 Added 3.54%
11,424 $705,000
Q2 2022

Aug 08, 2022

BUY
$57.72 - $65.01 $67,994 - $76,581
1,178 Added 11.95%
11,033 $682,000
Q1 2022

Apr 26, 2022

BUY
$57.92 - $72.58 $570,801 - $715,275
9,855 New
9,855 $580,000
Q1 2020

Apr 23, 2020

SELL
$62.63 - $80.22 $86,429 - $110,703
-1,380 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $85,035 - $93,536
1,380 New
1,380 $88,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Argent Advisors, Inc. Portfolio

Follow Argent Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Argent Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Argent Advisors, Inc. with notifications on news.